Total Payments
$4,253
2024 Payments
$639.56
Companies
20
Transactions
277
Medicare Patients
513
Medicare Billing
$64,361
Payment Breakdown by Category
Food & Beverage$4,193 (98.6%)
Education$59.98 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,193 | 275 | 98.6% |
| Education | $59.98 | 2 | 1.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alkermes, Inc. | $755.51 | 45 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $524.20 | 35 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $476.72 | 39 | $0 (2022) |
| Otsuka America Pharmaceutical, Inc. | $456.55 | 28 | $0 (2024) |
| ABBVIE INC. | $409.91 | 20 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $307.74 | 23 | $0 (2024) |
| ITI, Inc. | $277.11 | 32 | $0 (2023) |
| Vanda Pharmaceuticals Inc. | $219.17 | 11 | $0 (2024) |
| Neurocrine Biosciences, Inc. | $201.30 | 12 | $0 (2024) |
| Allergan Inc. | $124.02 | 6 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $639.56 | 31 | Alkermes, Inc. ($149.22) |
| 2023 | $808.17 | 50 | Alkermes, Inc. ($198.27) |
| 2022 | $1,050 | 85 | Alkermes, Inc. ($200.57) |
| 2021 | $381.99 | 24 | Sunovion Pharmaceuticals Inc. ($118.49) |
| 2020 | $57.04 | 4 | Sunovion Pharmaceuticals Inc. ($26.07) |
| 2019 | $393.90 | 27 | Alkermes, Inc. ($82.35) |
| 2018 | $577.83 | 31 | Neuronetics, Inc. ($92.35) |
| 2017 | $344.42 | 25 | Sunovion Pharmaceuticals Inc. ($166.10) |
All Payment Transactions
277 individual payment records from CMS Open Payments — Page 1 of 12
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Vanda Pharmaceuticals Inc. | HETLIOZ (Drug), FANAPT | Food and Beverage | In-kind items and services | $35.45 | General |
| Category: NON-24-HOUR SLEEP-WAKE DISORDER | ||||||
| 12/12/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $14.96 | General |
| Category: Neuropsychiatry | ||||||
| 12/03/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $21.88 | General |
| Category: CNS | ||||||
| 12/03/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $18.16 | General |
| Category: Neuroscience | ||||||
| 11/14/2024 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $17.39 | General |
| 10/03/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $18.26 | General |
| Category: Neuropsychiatry | ||||||
| 10/02/2024 | Alkermes, Inc. | VIVITROL (Drug) | Food and Beverage | In-kind items and services | $0.60 | General |
| Category: CNS | ||||||
| 09/27/2024 | Alkermes, Inc. | VIVITROL (Drug) | Food and Beverage | In-kind items and services | $16.51 | General |
| Category: CNS | ||||||
| 09/26/2024 | Otsuka America Pharmaceutical, Inc. | ABILIFY MAINTENA (Drug), ABILIFY ASIMTUFII | Food and Beverage | In-kind items and services | $15.93 | General |
| Category: PSYCHIATRY | ||||||
| 09/19/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $13.87 | General |
| Category: Neuropsychiatry | ||||||
| 09/06/2024 | Vanda Pharmaceuticals Inc. | HETLIOZ (Drug), FANAPT | Food and Beverage | In-kind items and services | $35.88 | General |
| Category: NON-24-HOUR SLEEP-WAKE DISORDER | ||||||
| 08/29/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $16.90 | General |
| Category: Central Nervous System | ||||||
| 08/22/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $22.84 | General |
| Category: NEUROSCIENCE | ||||||
| 07/09/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $20.21 | General |
| Category: Neuropsychiatry | ||||||
| 06/26/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $28.20 | General |
| Category: CNS | ||||||
| 06/13/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $14.24 | General |
| Category: Central Nervous System | ||||||
| 06/12/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $19.10 | General |
| Category: PSYCHIATRY | ||||||
| 05/23/2024 | Lundbeck LLC | REXULTI (Drug) | Food and Beverage | Cash or cash equivalent | $29.99 | General |
| Category: PSYCHIATRY | ||||||
| 05/23/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $28.41 | General |
| Category: CNS | ||||||
| 04/23/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $19.63 | General |
| Category: Neuroscience | ||||||
| 04/03/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.09 | General |
| Category: NEUROSCIENCE | ||||||
| 03/28/2024 | Teva Pharmaceuticals USA, Inc. | Austedo XR (Drug) | Food and Beverage | In-kind items and services | $31.37 | General |
| Category: Central Nervous System | ||||||
| 03/26/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $13.80 | General |
| Category: Neuroscience | ||||||
| 03/12/2024 | Janssen Pharmaceuticals, Inc | SPRAVATO (Drug) | Food and Beverage | In-kind items and services | $16.80 | General |
| Category: Neuroscience | ||||||
| 03/07/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $25.13 | General |
| Category: CNS | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 121 | 315 | $51,873 | $18,685 |
| 2022 | 3 | 85 | 237 | $29,558 | $12,485 |
| 2021 | 3 | 112 | 271 | $31,866 | $16,037 |
| 2020 | 6 | 195 | 353 | $46,463 | $17,154 |
Total Patients
513
Total Services
1,176
Medicare Billing
$64,361
Procedure Codes
16
All Medicare Procedures & Services
16 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 39 | 144 | $25,008 | $8,188 | 32.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 42 | 129 | $12,900 | $6,636 | 51.4% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 19 | 21 | $10,290 | $2,599 | 25.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 21 | 21 | $3,675 | $1,262 | 34.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 45 | 127 | $12,715 | $6,893 | 54.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 25 | 89 | $14,743 | $4,884 | 33.1% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 15 | 21 | $2,100 | $707.82 | 33.7% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 51 | 131 | $13,300 | $7,399 | 55.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 41 | 69 | $6,795 | $4,761 | 70.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 20 | 71 | $11,771 | $3,877 | 32.9% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2020 | 54 | 127 | $12,900 | $6,869 | 53.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 26 | 93 | $15,345 | $5,422 | 35.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2020 | 21 | 27 | $4,482 | $1,540 | 34.4% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 42 | 49 | $4,900 | $1,505 | 30.7% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2020 | 14 | 14 | $4,536 | $1,478 | 32.6% |
| 99421 | Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 5-10 minutes | Office | 2020 | 38 | 43 | $4,300 | $340.82 | 7.9% |
About Dr. Zafar Mahmood, MD
Dr. Zafar Mahmood, MD is a Psychiatry healthcare provider based in Kansas City, Missouri. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1952361545.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Zafar Mahmood, MD has received a total of $4,253 in payments from pharmaceutical and medical device companies, with $639.56 received in 2024. These payments were reported across 277 transactions from 20 companies. The most common payment nature is "Food and Beverage" ($4,193).
As a Medicare-enrolled provider, Mahmood has provided services to 513 Medicare beneficiaries, totaling 1,176 services with total Medicare billing of $64,361. Data is available for 4 years (2020–2023), covering 16 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Kansas City, MO
- Active Since 03/27/2006
- Last Updated 11/16/2010
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1952361545
Products in Payments
- VRAYLAR (Drug) $533.93
- ARISTADA (Drug) $532.48
- LATUDA (Drug) $476.72
- REXULTI (Drug) $380.38
- CAPLYTA (Drug) $317.34
- AUSTEDO (Drug) $245.23
- SPRAVATO (Drug) $244.41
- INVEGA SUSTENNA (Drug) $239.09
- INGREZZA (Drug) $201.30
- ABILIFY MAINTENA (Drug) $155.65
- Fanapt (Drug) $131.84
- NEUROSTAR TMS THERAPY (Device) $92.35
- HETLIOZ (Drug) $87.33
- LYBALVI (Drug) $85.18
- Aristada 441 mg (Drug) $83.33
- Austedo XR (Drug) $62.51
- Trintellix (Drug) $61.93
- AZSTARYS (Drug) $55.23
- INVEGA TRINZA (Drug) $40.70
- TRINTELLIX (Drug) $34.16
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Kansas City
Dr. Brian Barash, M.d, M.D
Psychiatry — Payments: $825,527
Psychiatry $825,527
Debra Kelsh, M.d, M.D
Psychiatry — Payments: $36,659
Psychiatry $36,659
Mark Cannon, M.d, M.D
Psychiatry — Payments: $18,944
Psychiatry $18,944
Dr. Asim Ulusarac, M.d, M.D
Psychiatry — Payments: $12,464
Psychiatry $12,464
Dr. Tomas Brillantes, M.d, M.D
Psychiatry — Payments: $11,385
Psychiatry $11,385
Christine Trueblood, M.d, M.D
Psychiatry — Payments: $10,633
Psychiatry $10,633